Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

Peptides

Volumn 30, Issue 12, 2009, Pages 2357-2364

  Fernández Martínez, Ana B ^a   Bajo, Ana M ^a   Valdehita, Ana ^a   Isabel Arenas, M ^a   Sánchez Chapado, Manuel ^a,b   Carmena, María J ^a   Prieto, Juan C ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

COX 2; Curcumin; Matrix metalloproteinases; Prostate cancer; VIP

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONE ACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; CYCLOOXYGENASE 2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NITROBENZENES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SULFONAMIDES; VASOACTIVE INTESTINAL PEPTIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 70449687867     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.09.018     Document Type: Article

References (35)

1. Aggarwal B.B., and Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry and Cell Biology 41 (2009) 40-59
2. Chang J.T., Chen I.H., Liao C.T., Wang H.M., Hsu Y.M., Hung K.F., et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clinical Biochemistry 35 (2002) 591-596
3. Clarke N.W., Hart C.A., and Brown M.D. Molecular mechanisms of metastasis in prostate cancer. Asian Journal of Andrology 11 (2009) 57-67
4. Collado B., Carmena M.J., Clemente C., Prieto J.C., and Bajo A.M. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 28 (2007) 1896-1901
5. Collado B., Carmena M.J., Sánchez-Chapado M., Ruíz-Villaespesa A., Bajo A.M., Fernández-Martínez A.B., et al. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology 26 (2005) 1629-1635
6. Collado B., Gutiérrez-Cañas I., Rodríguez-Henche N., Carmena M.J., and Prieto J.C. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regulatory Peptides 119 (2004) 69-75
7. Collado B., Sanchez-Chapado M., Prieto J.C., and Carmena M.J. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Molecular and Cellular Endocrinology 249 (2006) 116-122
8. Dorai T., Cao Y.C., Dorai B., Buttyan R., and Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47 (2001) 293-303
9. Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cells. Prostate 69 (2009) 774-786
10. Fernandez-Martinez A.B., Collado B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression. Molecular and Cellular Endocrinology 270 (2007) 8-16
11. Garcia-Fernandez M.O., Solano R.M., Carmena M.J., Busto R., Bodega G., Ruíz-Villaespesa A., et al. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24 (2003) 893-902
12. Gately S., and Li W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology 31 (2004) 2-11
13. Grau R., Diaz-Muñoz M.D., Cacheiro-Llaguno C., Fresno M., and Iñiguez M.A. Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Research (2008) 352437
14. Gutiérrez-Cañas I., Rodríguez-Henche N., Bolaños O., Carmena M.J., Prieto J.C., and Juarranz M.G. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology 139 (2003) 1050-1058
15. Hsu S.M., and Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. Journal of Histochemistry and Cytochemistry 30 (1982) 1079-1082
16. Huang M.T., Smart R.C., Wong C.Q., and Conney A.H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Research 48 (1988) 5941-5946
17. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
18. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 (2008) 71-96
19. Khor T.O., Keum Y.S., Lin W., Kim J.H., Hu R., Shen G., et al. Combined inhibitory effects of curcumin and phenetyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mouse. Cancer Research 66 (2006) 613-621
20. Klein T., Shephard P., Kleinert H., and Kömhoff M. Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochimica et Biophysica Acta 1773 (2007) 1605-1608
21. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clinical Cancer Research 13 (2007) 3423-3430
22. Nelson W.G., DeWeese T.L., and De Marzo A.M. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Reviews 21 (2002) 3-16
23. Redding T.W., and Schally A.V. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America 80 (1983) 1459-1462
24. Reuter S., Eifes S., Dicato M., Aggarwal B.B., and Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochemical Pharmacology 76 (2008) 1340-1351
25. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
26. Said S.I. Molecules that protect: the defense of neurons and other cells. Journal of Clinical Investigation 97 (1996) 2163-2164
27. Sciarra A., Mariotti G., Salciccia S., Gomez A.A., Monti S., Toscano V., et al. Prostate growth and inflammation. Journal of Steroid Biochemistry and Molecular Biology 108 (2008) 254-260
28. Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., and Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 66 (2005) 1239-1244
29. Tanabe T., and Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins and Other Lipid Mediators 68 (2002) 95-114
30. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
31. Wagner M., Loos J., Weksler N., Gantner M., Corless C.L., and Barry J.M. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 332 (2005) 800-807
32. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 2692-2696
33. Xu X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 13 (2002) 127-137
34. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., and De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Letters 215 (2004) 1-20
35. Zhu Y.M., Azahri N.S., Yu D.C., and Woll P.J. Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer 8 (2008) 218